Butterfly Network Participates in Research Initiative Examining AI-Enhanced POCUS for Early Tuberculosis Detection in Sub-Saharan Africa | Intellectia.AI
Butterfly Network Participates in Research Initiative Examining AI-Enhanced POCUS for Early Tuberculosis Detection in Sub-Saharan Africa
Written by Emily J. Thompson, Senior Investment Analyst
Butterfly Network's Role in TB Research: Butterfly Network, Inc. is participating in the CAD LUS4TB study to evaluate AI-assisted point-of-care ultrasound for tuberculosis triage in under-resourced regions, particularly Sub-Saharan Africa.
Critical Need for Diagnostic Tools: With 2.5 million TB cases reported in Africa in 2022, there is an urgent need for accessible diagnostic tools in primary care settings lacking ultrasound capabilities.
AI-Enabled Ultrasound Implementation: The trial will involve 3,000 adult patients and utilize AI-led POCUS to help non-radiologist healthcare workers detect TB indicators without extensive training or lab access.
Long-Term Goals and Innovations: The initiative aims to support policy development for AI-aided lung ultrasound in TB management, while Butterfly continues to innovate with its handheld ultrasound technology to improve global health equity.
BFLY
$3.045+Infinity%1D
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFLY is 4.25 USD with a low forecast of 4.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BFLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFLY is 4.25 USD with a low forecast of 4.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.010
Low
4.00
Averages
4.25
High
4.50
Current: 3.010
Low
4.00
Averages
4.25
High
4.50
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$2
2025-11-03
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$2
2025-11-03
maintain
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Butterfly Network to $3.25 from $2 and keeps a Buy rating on the shares following Q3 results, which came in largely in-line as the company continues to work through macroeconomic headwinds impacting hospital purchasing decisions. Revenue of $21.5M and adjusted EBITDA of ($8.1M) both beat consensus expectations, and management reiterated FY25 guidance, signaling confidence in a sequential pick-up for Q4 as pipeline activity improves and year-end capital cycles approach, Craig-Hallum adds.
Craig-Hallum
Buy
downgrade
$3 -> $2
2025-08-04
Reason
Craig-Hallum
Price Target
$3 -> $2
2025-08-04
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on Butterfly Network to $2 from $3 and keeps a Buy rating on the shares following Q2 earnings, which were largely in line with expectations. The firm notes the stock declined following the print, reflecting investor disappointment with the reduced growth outlook. Craig-Hallum views the guide down as driven by macro issues at customers rather than platform or competitive concerns and maintains a positive long-term view.
Outperform -> Perform
downgrade
2025-08-01
Reason
Price Target
2025-08-01
downgrade
Outperform -> Perform
Reason
Oppenheimer downgraded Butterfly Network to Perform from Outperform.
Oppenheimer
Oppenheimer
Outperform -> Perform
downgrade
$1.50
2025-08-01
Reason
Oppenheimer
Oppenheimer
Price Target
$1.50
2025-08-01
downgrade
Outperform -> Perform
Reason
Oppenheimer downgraded Butterfly Network to Perform from Outperform following the Q2 report. The stock in afternoon trading is down 13% to $1.50. The company reduced its fiscal 2025 due to extended sales cycles amid funding and macro uncertainty, which management expects to persist through year-end, the analyst tells investors in a research note. The firm sees execution risk along with "lackluster" growth and moved to the sidelines pending greater confidence in Butterfly's growth prospects.
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
